重复皮下注射氯胺酮治疗难治性抑郁的开放标签扩展研究
本研究为KADS随机对照试验的开放标签扩展,纳入130例难治性抑郁患者,接受4周皮下消旋氯胺酮治疗(固定或灵活方案)。治疗结束时30%应答,4周后降至17%,超过50%患者MADRS减分不足25%;既往氯胺酮暴露仅首次治疗时应答短暂降低,无意外安全事件。
要点
- 4周皮下氯胺酮治疗难治性抑郁短期应答率30%,停药4周后降至17%。
- 超过50%患者MADRS减分不足25%,提示多数获益有限。
- 固定与灵活方案应答无差异,既往氯胺酮暴露不影响总体结局。
核心结论
- 在高治疗抵抗样本中,4周皮下消旋氯胺酮仅使少数患者获得短期临床获益,停药后应答率显著下降,无意外安全事件。
研究设计与样本
- 研究为随机对照试验(KADS)的开放标签扩展(OLE),在澳大利亚和新西兰7个心境障碍中心开展。
- 纳入130例试验参与者,其试验后评估MADRS评分≥20,其中32例接受固定方案,98例接受灵活方案。
主要发现
- 治疗结束时30%(36/116)患者应答(MADRS减分≥50%),4周后17%(19/110)仍为应答者。
- 超过50%患者MADRS减分不足25%。
- 固定方案与灵活方案在各时间点的抑郁应答无差异。
- 随机对照试验期间接受氯胺酮者在OLE首次治疗后出现短暂应答降低,其他评估点无差异。
- 无自杀或需住院的自杀行为报告,仅观察到预期副作用。
关键数值与推荐
- 初始方案为每周两次皮下消旋氯胺酮0.5 mg/kg,固定方案持续4周。
- 经数据安全监查委员会建议后改为灵活方案:0.5-0.9 mg/kg,根据应答引导增量。
- 应答定义为MADRS减分≥50%。
临床怎么用
- 对高度难治性抑郁患者,4周皮下氯胺酮方案可能使少数人短期获益,但停药后应答率明显下降。
- 既往氯胺酮暴露不显著影响后续OLE结局,但首次治疗应答可能短暂降低。
- 治疗期间未出现意外安全信号,但仍需监测预期副作用。
局限性
- 开放标签扩展设计,无对照,可能存在偏倚。
- 样本来自随机对照试验参与者,选择偏倚可能影响外推性。
- 探索性亚组分析,既往氯胺酮暴露与结局的关联需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Longer-term outcome and safety data of repeated subcutaneous racemic ketamine for treatment-resistant depression (TRD) is lacking, as is knowledge of the impact of prior ketamine treatment on subsequent response. AIMS: To evaluate the effectiveness and safety of a 4-week course of subcutaneous racemic ketamine over 6 months and investigate whether prior ketamine treatment influences treatment response. METHOD: An open label extension (OLE) of a randomised controlled trial (RCT) was conducted at seven mood disorder centres in Australasia, enrolling consenting trial participants who had a Montgomery-Åsberg Depression Rating Scale (MADRS) score of ≥20 at post-trial assessment. Participants initially received twice-weekly 0.5 mg/kg subcutaneous racemic ketamine (fixed regimen) for 4 weeks. Dosing was revised after a Data Safety Monitoring Board recommendation, to a 'flexible regimen' (0.5-0.9 mg/kg with response-guided increments). Depression and safety outcomes were assessed throughout treatment, and 4 weeks and 6 months later. RESULTS: 130 RCT participants entered the OLE phase of whom 32 underwent the fixed OLE regimen and 98 the flexible regimen. At treatment end, 30% (36/116) had responded (MADRS reduction ≥50%), and 4 weeks later 17% (19/110) were 'responders'. Over 50% experienced <25% MADRS reduction. There was no difference in depression response at any time point between regimens. Those treated with ketamine during the RCT showed a transient reduced response after first OLE treatment but at no other assessment point. There were no reports of suicide or suicidal behaviour requiring admission and only expected side-effects observed. CONCLUSIONS: In a highly treatment-resistant sample, a 4-week course of subcutaneous racemic ketamine produced short-term clinical benefit in a minority of participants, with response rates declining substantially after treatment cessation, and no unexpected safety concerns. Exploratory subgroup analyses showed no association between prior RCT ketamine exposure and OLE outcomes. TRIAL REGISTRATION: ACTRN12616001096448 at www.anzctr.org.au.
引用
- Glozier N, Morris R, Stratton E, et al. Effectiveness and safety of repeat dose subcutaneous ketamine for treatment-resistant depression, and the impact of prior ketamine treatment: open label extension of the KADS study. Br J Psychiatry. 2026. PMID: 42403004. doi:10.1192/bjp.2026.10692
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。